Dr. Reddys Laboratories
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Dr. Reddy's Laboratories is currently navigating a challenging landscape characterized by supply disruptions in semaglutide and declining revenues from lenalidomide. Management remains optimistic about medium-term growth, driven by a robust pipeline of new product launches, particularly in biosimilars and complex generics. The anticipated U.S. approval of the abatacept biosimilar by December 2026 is expected to enhance Dr. Reddy's competitive position in the biologics market. However, pricing pressures in the U.S. generics sector and geopolitical risks pose significant challenges. Vista's forecast reflects a cautious outlook, with expected revenue contraction and margin pressures over the next 12-24 months. The company's balance sheet remains conservatively financed, supporting its strategic initiatives. While the industry is expanding, Dr. Reddy's must address execution risks related to semaglutide and maintain operational efficiencies to stabilize margins. Key opportunities include the successful re-launch of semaglutide and the commercialization of abatacept, while headwinds include competitive pressures and ongoing pricing erosion. Overall, Dr. Reddy's is positioned for long-term growth, but must navigate several near-term challenges to realize its potential
Why We Like This Stock
- Anticipated U.S. approval of the abatacept biosimilar could enhance market positioning
- Strong growth potential in emerging markets and a robust pipeline of new product launches
- Management's focus on operational efficiencies and maintaining a conservatively financed balance sheet supports strategic initiatives
Things To Watch Out For
- Supply disruptions in semaglutide have led to a downward revision of revenue expectations
- Ongoing pricing pressures in the U.S. generics market could impact margins
- Geopolitical risks and execution challenges pose significant threats to achieving strategic objectives
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 28,011 | 32,644 | 33,700 | 32,023 | 35,171 |
| Profit Before Tax (Cr.) | 7,111 | 7,529 | 5,393 | 1,669 | 4,474 |
| PBT Margin | 25.4% | 23.1% | 1600.3% | 5.2% | 12.7% |
| Net Profit (Cr.) | 5,189 | 5,314 | 4,158 | 1,285 | 3,413 |
| Earnings Per Share | 62.1 | 62.8 | 50.3 | 15.2 | 40.9 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| BofA | ▲ Buy | 1,480 | 23-Jul-2026 |
| CLSA | ► Hold | 1,240 | 23-Jul-2026 |
| Choice Equity | ► Add | 1,305 | 23-Jul-2026 |
| Citigroup | ▼ Sell | 1,040 | 23-Jul-2026 |
| Deven Choksey | ► Accumulate | 1,291 | 24-Jul-2026 |
| Emkay Global | ▼ Reduce | 1,200 | 23-Jul-2026 |
| Goldman Sachs | ▼ Reduce | 1,075 | 24-Apr-2026 |
| HSBC | ▲ Buy | 1,460 | 10-Jul-2026 |
| ICICI Securities | ► Add | 1,275 | 23-Jul-2026 |
| JPMorgan | ▼ Underweight | 1,100 | 23-Jul-2026 |
| Jeffries | ▼ Underperform | 1,040 | 23-Jul-2026 |
| Kotak Securities | ▼ Reduce | 1,125 | 23-Jul-2026 |
| Moneycontrol | ► Equalweight | nan | 23-Jul-2026 |
| Morgan Stanley | ► Equalweight | 1,200 | 23-Jul-2026 |
| Motilal Oswal | ► Neutral | 1,210 | 10-Jul-2026 |
| Nomura | ▲ Buy | 1,740 | 22-Jun-2026 |
| Prabhudas Liladhar | ► Accumulate | 1,300 | 23-Jul-2026 |
| UBS | ▼ Sell | 1,150 | 23-Jul-2026 |
Company Overview
Show Company Profile
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.